Comprehensive Hernia Center, Digestive Disease and Surgery Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, A-100, Cleveland, OH, 44195, USA.
Department of Hematology and Medical Oncology, Hospital Amaral Carvalho, Jau, Brazil.
Surg Endosc. 2019 Feb;33(2):475-485. doi: 10.1007/s00464-018-6321-y. Epub 2018 Jul 9.
The advent of newer second-line medical therapies (SLMT) for immune thrombocytopenia (ITP) has contributed to decreased rates of splenectomy, following a trend to avoid or delay surgery. We aimed to characterize the long-term outcomes of laparoscopic splenectomy (LS) for ITP at our institution, examining differences in LS efficiency when performed before or after SLMTs.
Adults with primary ITP who underwent LS between 2002 and 2016 were identified. Retrospective review of electronic medical records was supplemented with telephone interviews. Treatment response was defined according to current guidelines as complete responders (CR), responders (R), and non-responders (NR). Kaplan-Meier estimates assessed relapse-free rates, and predictors of long-term response were investigated using logistic regression.
109 patients met inclusion criteria, from which 42% were treated with an SLMT before referral to LS. LS was completed in all cases, with no conversions or intraoperative complications. The perioperative morbidity was 7.3%, including 3 deep vein and 2 portal vein thrombosis, one reoperation for bleeding, and no mortalities. Splenectomy was initially effective in 99 patients (CR + R = 90.8%), and 10 patients were NR. At a median 62-month follow-up, 25 patients relapsed, resulting in a 68% CR + R rate. Proportion of CR + R was similar in patients who previously received SLMT and those who did not (61 vs. 76.7%, p = 0.08). CR + R patients were younger (45 vs. 53, p = 0.03), had higher preoperative platelet counts (36 vs. 19, p = 0.01), and experienced a higher increment in platelet counts during hospital stay (117 vs. 38, p < 0.001) as well as 30-days postoperatively (329 vs. 124, p < 0.001). Only a robust response in platelet count at 30-days postoperatively was independently associated with long-term response (OR 1.005, p = 0.006).
LS was curative in 68% of patients, with no statistically significant difference when performed before or after SLMTs. Outcomes remain challenging to predict preoperatively, with only a robust increase in platelet counts on short term being associated with long-term response.
随着新型二线医学疗法(SLMT)在免疫性血小板减少症(ITP)中的应用,脾切除术的比例有所下降,趋势是避免或延迟手术。我们旨在描述本机构腹腔镜脾切除术(LS)的长期疗效,检查 SLMT 前后 LS 效率的差异。
确定了 2002 年至 2016 年间接受 LS 的原发性 ITP 成人患者。通过电子病历回顾补充了电话访谈。根据当前指南,将治疗反应定义为完全缓解(CR)、缓解(R)和无反应(NR)。使用 Kaplan-Meier 估计评估无复发生存率,并使用逻辑回归分析长期反应的预测因素。
109 例患者符合纳入标准,其中 42%在转诊至 LS 前接受了 SLMT 治疗。所有病例均完成 LS,无转换或术中并发症。围手术期发病率为 7.3%,包括 3 例深静脉血栓形成和 2 例门静脉血栓形成、1 例再出血,无死亡。脾切除术最初对 99 例患者(CR+R=90.8%)有效,10 例患者无反应。中位 62 个月随访时,25 例患者复发,CR+R 率为 68%。在先前接受 SLMT 和未接受 SLMT 的患者中,CR+R 的比例相似(61%与 76.7%,p=0.08)。CR+R 患者年龄较小(45 岁与 53 岁,p=0.03),术前血小板计数较高(36 与 19,p=0.01),住院期间血小板计数增加幅度较大(117 与 38,p<0.001),术后 30 天也较大(329 与 124,p<0.001)。只有术后 30 天血小板计数的强劲反应与长期反应独立相关(OR 1.005,p=0.006)。
LS 在 68%的患者中是治愈性的,在 SLMT 前后进行手术没有统计学上的显著差异。术前结果仍然难以预测,只有短期血小板计数的显著增加与长期反应相关。